Analyst firms · Robert W. Baird · BIIB

Robert W. Baird BIIB price target and rating history

Biogen Inc. (BIIB) · Health Care

Robert W. Baird rates Biogen Inc. (BIIB) Outperform with a $340 price target, as of its latest action on Sep 28, 2022. It has published 3 rating actions on BIIB since December 2021, including 1 upgrade and 0 downgrades. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

Current rating
Outperform
Price target
$340
Median target, all firms
$231.50
Actions on BIIB
3

Robert W. Baird price target on BIIB

$340$282$22420222023202420252026
Robert W. Baird price target on BIIB, each point a stated target, December 2021 to September 2022.

Every Robert W. Baird rating on BIIB

How other firms rate BIIB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$280Oct 29, 2026
Wolfe ResearchOutperform$300Aug 13, 2026
Truist SecuritiesBuy$235Jul 13, 2026
NeedhamBuy$255Jun 8, 2026
Evercore ISIOutperformMay 15, 2026
UBSBuy$225Apr 22, 2026
Wells FargoOverweight$250Apr 20, 2026
Piper SandlerOverweight$214Apr 14, 2026
BarclaysEqual Weight$185Feb 20, 2026
H.C. WainwrightBuy$228Feb 9, 2026
HSBCReduce$143Dec 10, 2025

Questions about Robert W. Baird and BIIB

What is Robert W. Baird's price target for BIIB?
Robert W. Baird's latest stated price target for Biogen Inc. (BIIB) is $340, from its action on Sep 28, 2022.
What is Robert W. Baird's rating on BIIB?
Robert W. Baird rates BIIB Outperform, a bullish rating, as of Sep 28, 2022.
When did Robert W. Baird last change its view on BIIB?
On Sep 28, 2022, Robert W. Baird upgrades to Outperform from Neutral, price target $224 to $340.
How does Robert W. Baird's BIIB target compare with other analysts?
Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

More BIIB rating histories

All Robert W. Baird ratingsBIIB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.